Genetic Association of the KLK4 Locus with Risk of Prostate Cancer

The Kallikrein-related peptidase, KLK4, has been shown to be significantly overexpressed in prostate tumours in numerous studies and is suggested to be a potential biomarker for prostate cancer. KLK4 may also play a role in prostate cancer progression through its involvement in epithelial-mesenchymal transition, a more aggressive phenotype, and metastases to bone. It is well known that genetic variation has the potential to affect gene expression and/or various protein characteristics and hence we sought to investigate the possible role of single nucleotide polymorphisms (SNPs) in the KLK4 gene in prostate cancer. Assessment of 61 SNPs in the KLK4 locus (±10 kb) in approximately 1300 prostate cancer cases and 1300 male controls for associations with prostate cancer risk and/or prostate tumour aggressiveness (Gleason score <7 versus ≥7) revealed 7 SNPs to be associated with a decreased risk of prostate cancer at the Ptrend<0.05 significance level. Three of these SNPs, rs268923, rs56112930 and the HapMap tagSNP rs7248321, are located several kb upstream of KLK4; rs1654551 encodes a non-synonymous serine to alanine substitution at position 22 of the long isoform of the KLK4 protein, and the remaining 3 risk-associated SNPs, rs1701927, rs1090649 and rs806019, are located downstream of KLK4 and are in high linkage disequilibrium with each other (r2≥0.98). Our findings provide suggestive evidence of a role for genetic variation in the KLK4 locus in prostate cancer predisposition.

[1]  R. Eeles,et al.  Common variation in Kallikrein genes KLK5, KLK6, KLK12, and KLK13 and risk of prostate cancer and tumor aggressiveness. , 2013, Urologic oncology.

[2]  Y. Homma,et al.  Oct1 regulates cell growth of LNCaP cells and is a prognostic factor for prostate cancer , 2012, International journal of cancer.

[3]  J. Clements,et al.  Human kallikrein 4 signal peptide induces cytotoxic T cell responses in healthy donors and prostate cancer patients , 2012, Cancer Immunology, Immunotherapy.

[4]  A. Scorilas,et al.  Kallikrein‐related peptidase 4 gene (KLK4) in prostate tumors: Quantitative expression analysis and evaluation of its clinical significance , 2011, The Prostate.

[5]  John T. Wei,et al.  A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. , 2011, The Journal of urology.

[6]  W. Willett,et al.  Large-scale exploration of gene-gene interactions in prostate cancer using a multistage genome-wide association study. , 2011, Cancer research.

[7]  S. Benlloch,et al.  Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript , 2011, Human Genetics.

[8]  A. Spurdle,et al.  Vascular endothelial growth factor gene polymorphisms and ovarian cancer survival. , 2010, Gynecologic oncology.

[9]  D. Altshuler,et al.  A map of human genome variation from population-scale sequencing , 2010, Nature.

[10]  S. Chambers,et al.  Diagnostic and treatment pathways for men with prostate cancer in Queensland: investigating spatial and demographic inequalities , 2010, BMC Cancer.

[11]  J. Clements,et al.  Kallikreins on steroids: structure, function, and hormonal regulation of prostate-specific antigen and the extended kallikrein locus. , 2010, Endocrine reviews.

[12]  Andrew J. Vickers,et al.  Blood Biomarker Levels to Aid Discovery of Cancer-Related Single-Nucleotide Polymorphisms: Kallikreins and Prostate Cancer , 2010, Cancer Prevention Research.

[13]  M. Wirth,et al.  Polyclonal antibodies against kallikrein-related peptidase 4 (KLK4): immunohistochemical assessment of KLK4 expression in healthy tissues and prostate cancer , 2010, Biological chemistry.

[14]  A. Scorilas,et al.  Prognostic value and biological role of the kallikrein-related peptidases in human malignancies. , 2010, Future oncology.

[15]  W. Han,et al.  Candidate gene approach evaluates association between innate immunity genes and breast cancer risk in Korean women. , 2009, Carcinogenesis.

[16]  J. Clements,et al.  Direct Progesterone Receptor and Indirect Androgen Receptor Interactions with the Kallikrein-Related Peptidase 4 Gene Promoter in Breast and Prostate Cancer , 2009, Molecular Cancer Research.

[17]  Andrew D. Johnson,et al.  SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap , 2008, Bioinform..

[18]  Christopher Phillips,et al.  SPSmart: adapting population based SNP genotype databases for fast and comprehensive web access , 2008, BMC Bioinformatics.

[19]  R. Eeles,et al.  Reply to “Variation in KLK genes, prostate-specific antigen and risk of prostate cancer” , 2008, Nature Genetics.

[20]  M. Thun,et al.  Variation in KLK genes, prostate-specific antigen and risk of prostate cancer , 2008, Nature Genetics.

[21]  R. Eeles,et al.  SNPs in the kallikrein gene region associated with prostate cancer risk: true cause or association by design? , 2008, Nature genetics.

[22]  Elaine A. Ostrander,et al.  Multiple Novel Prostate Cancer Predisposition Loci Confirmed by an International Study: The PRACTICAL Consortium , 2008, Cancer Epidemiology Biomarkers & Prevention.

[23]  G. Mize,et al.  Prostate-Specific Kallikreins-2 and -4 Enhance the Proliferation of DU-145 Prostate Cancer Cells through Protease-Activated Receptors-1 and -2 , 2008, Molecular Cancer Research.

[24]  H. Samaratunga,et al.  A novel transcript from the KLKP1 gene is androgen regulated, down‐regulated during prostate cancer progression and encodes the first non‐serine protease identified from the human kallikrein gene locus , 2008, The Prostate.

[25]  Ali Amin Al Olama,et al.  Multiple newly identified loci associated with prostate cancer susceptibility , 2008, Nature Genetics.

[26]  E. Diamandis,et al.  A consolidated catalogue and graphical annotation of dbSNP polymorphisms in the human tissue kallikrein (KLK) locus , 2007, Molecular oncology.

[27]  H. Danielsen,et al.  Kallikrein 4 is a proliferative factor that is overexpressed in prostate cancer. , 2007, Cancer research.

[28]  P. Fearnhead,et al.  Genome-wide association study of prostate cancer identifies a second risk locus at 8q24 , 2007, Nature Genetics.

[29]  J. Clements,et al.  Kallikrein 4 is a potential mediator of cellular interactions between cancer cells and osteoblasts in metastatic prostate cancer , 2007, The Prostate.

[30]  C. P. Morris,et al.  PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility. , 2006, Carcinogenesis.

[31]  A. Chokkalingam,et al.  Prostate cancer epidemiology. , 2006, Frontiers in bioscience : a journal and virtual library.

[32]  H. Samaratunga,et al.  Compartmentalized expression of kallikrein 4 (KLK4/hK4) isoforms in prostate cancer: nuclear, cytoplasmic and secreted forms. , 2005, Endocrine-related cancer.

[33]  J. Clements,et al.  Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells. , 2005, Endocrine-related cancer.

[34]  E. Diamandis,et al.  Human kallikrein 4: quantitative study in tissues and evidence for its secretion into biological fluids. , 2005, Clinical chemistry.

[35]  Thomas Werner,et al.  MatInspector and beyond: promoter analysis based on transcription factor binding sites , 2005, Bioinform..

[36]  G. Yousef,et al.  A survey of alternative transcripts of human tissue kallikrein genes. , 2005, Biochimica et biophysica acta.

[37]  Mark Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[38]  S. Brunak,et al.  Improved prediction of signal peptides: SignalP 3.0. , 2004, Journal of molecular biology.

[39]  M. W. Foster,et al.  Integrating ethics and science in the International HapMap Project , 2004, Nature Reviews Genetics.

[40]  M. Loda,et al.  Kallikrein 4 is a Predominantly Nuclear Protein and Is Overexpressed in Prostate Cancer , 2004, Cancer Research.

[41]  I. Kohane,et al.  A SNP-centric database for the investigation of the human genome , 2004, BMC Bioinformatics.

[42]  Toshihiro Tanaka The International HapMap Project , 2003, Nature.

[43]  Michael Zuker,et al.  Mfold web server for nucleic acid folding and hybridization prediction , 2003, Nucleic Acids Res..

[44]  S. Reed,et al.  Characterization of KLK4 expression and detection of KLK4-specific antibody in prostate cancer patient sera , 2002, Oncogene.

[45]  C. Stephan,et al.  Detection of human kallikrein 4 in healthy and cancerous prostatic tissues by immunofluorometry and immunohistochemistry. , 2002, Clinical chemistry.

[46]  P. Carpenter,et al.  A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. , 2001, Cancer research.

[47]  D. Robins,et al.  Oct-1 Preferentially Interacts with Androgen Receptor in a DNA-dependent Manner That Facilitates Recruitment of SRC-1* , 2001, The Journal of Biological Chemistry.

[48]  G. Yousef,et al.  Prostase/KLK-L1 is a new member of the human kallikrein gene family, is expressed in prostate and breast tissues, and is hormonally regulated. , 1999, Cancer research.

[49]  L. Hood,et al.  Molecular cloning and characterization of prostase, an androgen-regulated serine protease with prostate-restricted expression. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[50]  Elizabeth M. Smigielski,et al.  dbSNP: the NCBI database of genetic variation , 2001, Nucleic Acids Res..

[51]  T. Heinemeyer,et al.  Databases on transcriptional regulation: TRANSFAC, TRRD and COMPEL , 1998, Nucleic Acids Res..